Relmada acquires Sepranolone for €3M; Phase 2b-ready for Tourette syndrome

RELMADA THERAPEUTICS, INC.

Acquired Sepranolone (GAMSA neurosteroid) from Asarina Pharma AB for €3 million; €2.756M due within 10 business days.
Phase 2a data: 28% reduction in tic severity (YGTSS, p=0.051); 69% greater quality-of-life improvement vs standard of care.
Phase 2b-ready asset for Tourette syndrome and other compulsive disorders; no CNS off-target effects in Phase 2a.
Relmada to host investor update on next development steps later in 2025.
Deal includes full global ownership rights; Asarina retains pre-closing liabilities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.